DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Lancet JE, Uy GL, Cortes JE. et al.
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.
J Clin Oncol 2016;
34: 7000 . doi:10.1200/JCO.2016.34.15_suppl.7000
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.